Previous Close | 0.3500 |
Open | 0.3600 |
Bid | 0.3500 x 1800 |
Ask | 0.3597 x 2200 |
Day's Range | 0.3401 - 0.3635 |
52 Week Range | 0.2190 - 1.1600 |
Volume | |
Avg. Volume | 1,333,340 |
Market Cap | 60.272M |
Beta (5Y Monthly) | 0.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1370 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for TYME
Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come.
Syros Pharmaceuticals is set to acquire a New Jersey biotech firm called Tyme Technologies Inc., extending its cash runway into 2025 at a time when biotech stocks are being hammered.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses currently estimated to be approximately $60 million. Syros expects to issue approximately 74.3 million shares. TYME stockholders are expected to receive approximately 0.4312 shares of Syros shares for each share of TYME share. The combined company will be led by Syros' existing management team, inc